News Category: Press Release

Scripps Research scientists train the immune system to make antibodies against numerous HIV strains

Joan Pulupa joins Scripps Research faculty to study the organization of DNA in brain cells and its links to neurodegeneration

Scripps Research scientists awarded $2M to advance global disease surveillance

Scripps Research scientists demonstrate a faster, cheaper route to making critical drugs using common table sugar

New method illustrates how to build a tough chemical bond found in carbohydrate-based drugs, such as those for treating diabetes.

Back in action: Researchers make drug-resistant bacteria vulnerable again

New findings from Scripps Research show that disabling a single bacterial protein can restore vancomycin’s power against resistant bacteria–and point to a new strategy for overcoming antibiotic resistance.

Molecular scissors caught in action: A structural blueprint for RNA therapeutics

A Scripps Research team has captured the first high-resolution structural images of human Argonaute 2 in its cutting-ready state, revealing why some small interfering RNA (siRNA) molecules work better than others and how to design more effective ones for this emerging therapy.

Immune molecule may drive excessive drinking in alcohol use disorder

Scripps Research scientists showed that blocking an immune molecule tied to inflammation reduced alcohol consumption in mice.

Newly identified molecule strengthens the eye’s response to damage in retinal disease

Scripps Research discovery finds that restoring the naturally occurring compound erucamide in the eye stabilized tissue in preclinical models of retinal degeneration.

Lab studies explain how new cancer drug works as it enters patient testing

Immunologists at Scripps Research show how a new, experimental drug revives immune cells to fight cancer.

Calibr-Skaggs awarded $5.1M by NIH to develop long-acting hepatitis B virus therapy

A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV.